Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy

Completed · Phase 3 · Has a placebo group

Conditions studied: Proliferative Diabetic Retinopathy, Diabetic Macular Edema

In brief

The purpose of the study is to find out if treatment with an intravitreal injection of triamcinolone or an intravitreal injection of ranibizumab can prevent loss of vision caused by panretinal photocoagulation treatment. At the present time, it is not known whether intravitreal steroid or anti-vascular endothelial growth factor (anti-VEGF) injections are beneficial in preventing vision loss after panretinal photocoagulation (PRP) treatment. It is possible that one or both of the types of injections will prevent vision loss after PRP treatment. However, it is not known whether the benefits of the injections will outweigh the risks. It is possible that because of side effects, the injections may not be as good as laser alone in treating the diabetic retinopathy.

Key facts

Study ID
NCT00445003
Run by
Jaeb Center for Health Research
People needed
333
Starts
2007-03-01
Expected to finish
2010-07-01
Last updated by the study team
2016-08-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.